PharmaCyte Biotech Inc (PMCB)

Currency in USD
0.4597
+0.0357(+8.42%)
Closed·
0.4820+0.0223(+4.85%)
·
Advertisement
Earnings results expected today
Unusual trading volume
PMCB is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.40890.4776
52 wk Range
0.33391.5100
Key Statistics
Prev. Close
0.4597
Open
0.412
Day's Range
0.4089-0.4776
52 wk Range
0.3339-1.51
Volume
470.78K
Average Volume (3m)
189.84K
1-Year Change
-53.0918%
Book Value / Share
2.6
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PMCB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

PharmaCyte Biotech Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Earnings

Latest Release
21/09/2026
EPS / Forecast
-0.54 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

Compare PMCB to Peers and Sector

Metrics to compare
PMCB
Peers
Sector
Relationship
P/E Ratio
−0.2x−4.0x−0.4x
PEG Ratio
0.00−0.020.00
Price/Book
0.2x1.2x2.6x
Price / LTM Sales
-10.1x3.0x
Upside (Analyst Target)
-244.0%54.3%
Fair Value Upside
Unlock−1.0%7.2%Unlock

PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company’s cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
184.38K1.72%84.76K
Other Institutional Investors
646.64K6.02%297.26K
Public Companies & Retail Investors
9.90M92.26%4.55M
Total
10.74M100.00%4.94M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Citadel Advisors LLC2.64%283,381130
Geode Capital Management, LLC1.16%124,24757

People Also Watch

3.840
RZLT
-2.78%
1.930
GRI
+4.89%
4.07
LENZ
-1.45%
0.36
BIOX
-2.72%
85.530
FEIM
+2.04%

FAQ

What Is the PharmaCyte Biotech (NASDAQ: PMCB) Share Price Today?

The PharmaCyte Biotech stock price today is 0.4597 USD.

What Stock Exchange Does PharmaCyte Biotech (PMCB) Trade On?

PharmaCyte Biotech is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for PharmaCyte Biotech?

The stock symbol (also called a 'ticker') for PharmaCyte Biotech is "PMCB."

What Is the Current PharmaCyte Biotech Market Capitalisation?

As of today, PharmaCyte Biotech (NASDAQ: PMCB) market cap is 4.9400M USD.

What Is PharmaCyte Biotech's (PMCB) Earnings Per Share (TTM)?

The PharmaCyte Biotech EPS is currently -2.2049 (Trailing Twelve Months).

When Is the Next PharmaCyte Biotech Earnings Date?

PharmaCyte Biotech's next earnings report will be released on 21/09/2026.

Is PMCB a Buy or Sell From a Technical Analyst Perspective?

Based on today's PharmaCyte Biotech moving averages and other technical indicators, the daily buy/sell signal for PMCB stock is Strong Sell.

How Many Times Has PharmaCyte Biotech Stock Split?

PharmaCyte Biotech has split 2 times. (See the PMCB stock split history page for full effective split date and price information.)

How Many Employees Does PharmaCyte Biotech Have?

PharmaCyte Biotech has 2 employees, based on their latest Companies House report.

What is the current trading status of PharmaCyte Biotech (NASDAQ: PMCB)?

As of 21/09/2026, PharmaCyte Biotech (PMCB) is trading at a share price of 0.4597 USD, with a previous close of 0.4597 USD. The stock has fluctuated within a day range of 0.4089 USD to 0.4776 USD, while its 52-week range spans from 0.3339 USD to 1.5100 USD.

What Is the PMCB Premarket Price?

PMCB's last pre-market stock price is 0.4820 USD. The pre-market share volume is 120.0000, and the stock has decreased by 0.0223, or 4.8500%.

What Is the PMCB After Hours Price?

PMCB's last after hours stock price is 0.4612 USD, the stock has decreased by 0.0015, or 0.3300%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.